
Opinion|Videos|May 1, 2024
Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera
Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
5

























